Answers are grounded in this paper and cite their sources.
Despite significant advances in treatments, colorectal cancer (CRC) remains a major health challenge due to high recurrence rates and resistance to therapy, highlighting an urgent need for more effective and safer treatments to improve patient survival. A significant barrier to developing novel therapies is the identification of suitable targets with expression restricted to cancerous tissue. Piwi-like RNA-mediated gene silencing 1 (PIWIL1) is a cancer-testis antigen with restricted expression in healthy adult testis but elevated expression in cancer, particularly CRC. Gene expression analysis indicated elevated PIWIL1 expression in colorectal, oesophageal, gastric and ovarian cancer, with retained expression in metastatic and pre-treated CRC tumours. In-situ hybridization revealed homogeneous PIWIL1 expression, particularly in colon cancer with approximately 50% of positive tumours irrespective of microsatellite status. We identified an HLA-A*02:01 PIWIL1 peptide presented in primary CRC tissue and cell lines and developed a TCR based bispecific T cell engager to redirect T cells against PIWIL1 presenting HLA-A*02:01 positive cancer cells. During affinity engineering of the PIWIL1 TCR, we identified cross-reactivity to a peptide derived from DOCK11, a commonly expressed protein, representing a potential safety risk. DOCK11 risk peptide was incorporated in the adopted engineering strategy to improve the safety and specificity of the soluble PIWIL1 TCR-T cell-engager. IMC-R117C, the selected candidate drug molecule, displayed high potency, specificity, and increased recognition and killing of cancer cells and patient derived organoids in vitro, further enhanced when combined with standard of care 5-Fluorouracil chemotherapy. IMC-R117C is currently under clinical investigation for advanced PIWIL1 positive cancers (NCT06840119).
No takes yet. Share an insight, caveat, or question.
Mai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: